Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Shares of medical technology major Becton, Dickinson and Company (BDX - Analyst Report) rose 0.5% following the announcement of its acquisition of San Jose, Calif.-based diagnostic instrument manufacturer, Alverix for a price tag of $40 million.

BDX has a long-term association with the privately held company Alverix. The former has been working the latter on BD Veritor System since 2008. BD Veritor System is used for detecting viral infections like influenza, streptococcus and respiratory syncytial virus.

Currently, Becton, Dickinson’s shares are hovering around a 52-week high. The last closing price of $111.08 represents a handsome one-year return of 39.4%.

BDX posted adjusted earnings per share of $1.58 for the fourth quarter of fiscal 2013, topping the Zacks Consensus Estimate of $1.47 as well as the year-ago earnings of $1.42 by 11.3%. Revenues in the quarter went up 6.8% to $2,101 million, also exceeding the Zacks Consensus Estimate of $2,045 million. In constant currency, revenues grew 7.2% in the quarter.

For fiscal 2013, adjusted earnings rose 10.8% to $5.95 per share from $5.37 per share in the prior fiscal year. Annual earnings surpassed the Zacks Consensus Estimate of $5.75. Revenues in the year rose 4.5% to $8,054 million.

For fiscal 2014, Becton Dickinson expects both reported and constant currency revenue growth in the range of 4.0 to 5.0%. BDX also anticipates adjusted earnings per share between $6.16 and $6.22 for the year, which tally with the Zacks Consensus Estimate of $6.21 and reflect year-over-year growth of 3.5% to 4.5%. The company revealed that the acquisition will not affect the fiscal year guidance.

BDX currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the medical/dental supplies industry include Align Technology Inc. (ALGN - Analyst Report), Cardinal Health, Inc. (CAH - Analyst Report), and McKesson Corporation (MCK - Analyst Report). Align Technology carries a Zacks Rank #1 (Strong Buy), while both Cardinal Health and McKesson hold a Zacks Rank #2 (Buy).
 

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GROUP DXYN 15.84 +7.90%
BOFL HOLDING BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%